NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Hoffmann-La Roche
Shanghai Henlius Biotech
Amgen
G1 Therapeutics, Inc.
G1 Therapeutics, Inc.
Hoffmann-La Roche
Incyte Corporation
University of Iowa
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
NanOlogy, LLC
AstraZeneca
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
BeiGene
Ipsen
Alliance for Clinical Trials in Oncology
Celgene
H. Lee Moffitt Cancer Center and Research Institute
Sellas Life Sciences Group
ETOP IBCSG Partners Foundation
University of Kentucky
National Institutes of Health Clinical Center (CC)
EMD Serono
Jiangsu HengRui Medicine Co., Ltd.
Jiangsu Simcere Pharmaceutical Co., Ltd.
ImmunityBio, Inc.
Advaxis, Inc.
Cancer Research and Biostatistics Clinical Trials Consortium
Exelixis
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Hoosier Cancer Research Network
Massachusetts General Hospital
Ludwig Institute for Cancer Research
Hoffmann-La Roche
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Incyte Corporation
Novartis
University of Colorado, Denver
Massachusetts General Hospital
SCRI Development Innovations, LLC
PharmaMar
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gilead Sciences
AbbVie